| Recruiting | Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention NCT06926595 | Milton S. Hershey Medical Center | Phase 2 |
| Not Yet Recruiting | Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant NCT05982275 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Phase 1 / Phase 2 |
| Withdrawn | A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treat NCT06297629 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT NCT06453460 | University of California, Irvine | Phase 2 |
| Completed | Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD NCT06093334 | University of Erlangen-Nürnberg Medical School | N/A |
| Recruiting | Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation NCT06028828 | University of California, Irvine | Phase 2 |
| Recruiting | Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transpl NCT05579639 | Children's Hospital Medical Center, Cincinnati | Phase 2 |
| Terminated | A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-a NCT05447663 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Unknown | Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill NCT05443854 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogen NCT04628338 | Sawa Ito, MD | EARLY_Phase 1 |
| Completed | Impact of COVID-19 Pandemic on Allogeneic Stem Cell Transplantation Organization : a French Experience NCT05088941 | Central Hospital, Nancy, France | — |
| Unknown | Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation NCT03964922 | Central Hospital, Nancy, France | N/A |
| Completed | Bisantrene for Relapsed /Refractory AML NCT03820908 | Sheba Medical Center | Phase 2 |
| Completed | CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia NCT03882203 | Shanghai Jiao Tong University School of Medicine | Phase 2 |
| Active Not Recruiting | Ruxolitinib + Allogeneic Stem Cell Transplantation in AML NCT03286530 | Massachusetts General Hospital | Phase 2 |
| Completed | Exercise Prior to Allogeneic Hematologic Stem Cell Transplantation NCT02273024 | University Health Network, Toronto | N/A |
| Completed | Role of Interferon-λ and Vaccine Response NCT03467074 | University Hospital, Basel, Switzerland | — |
| Completed | Immune Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation NCT03233659 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Unknown | Cognition in Allogeneic Stem Cell Transplanted Patients and Sports NCT02533947 | Universitätsklinikum Hamburg-Eppendorf | N/A |
| Completed | HHV-6-specific T-cell Reconstitution Among Children and Adolescents After Allogeneic Stem. NCT06256341 | Medical University of Graz | — |
| Completed | Caphosol® Versus State-of-the-art Mouthcare in Patients With Allogeneic Stem Cell Transplantation: a Randomize NCT01758562 | University of Zurich | N/A |
| Completed | Bortezomib to Treat Significant Complication of HSCT NCT01929980 | Children's Hospital Medical Center, Cincinnati | Phase 2 |
| Withdrawn | Autologous Cytomegalovirus (CMV) Specific CD8+ T Cells as Treatment for CMV Reactivation NCT01326273 | Imperial College London | Phase 1 / Phase 2 |
| Completed | Physical Exercise Therapy vs Relaxation in Allogeneic Stem Cell Transplantation (PETRA) NCT01374399 | German Cancer Research Center | N/A |
| Completed | Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. NCT00890500 | Fate Therapeutics | Phase 1 |
| Completed | Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells NCT01092026 | Universitair Ziekenhuis Brussel | N/A |
| Unknown | Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Mali NCT01212796 | Grupo Espanol de trasplantes hematopoyeticos y terapia celular | — |
| Terminated | Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation NCT01185223 | Pierrel Research Europe GmbH | Phase 3 |
| Unknown | Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itracon NCT01160952 | Guangzhou General Hospital of Guangzhou Military Command | Phase 2 |
| Unknown | Exercise During the Allogeneic Stem Cell Transplantation NCT00883714 | Charite University, Berlin, Germany | Phase 3 |
| Terminated | Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Tran NCT00737113 | Mitchell Horwitz, MD | Phase 1 |
| Completed | Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation NCT01560689 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Terminated | CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease NCT00611637 | H. Kim Lyerly | Phase 1 |
| Completed | Multimodal Intervention in Allogeneic Stem Cell Transplantation NCT00427115 | Rigshospitalet, Denmark | Phase 3 |
| Recruiting | CIBMTR Research Database NCT01166009 | Center for International Blood and Marrow Transplant Research | — |
| Recruiting | Protocol for a Research Sample Repository for Hematopoietic Cell Transplantation, Other Cellular Therapies and NCT04920474 | Center for International Blood and Marrow Transplant Research | — |
| Unknown | Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT) NCT00215007 | Charite University, Berlin, Germany | Phase 2 / Phase 3 |